Moreover, dissection of the gene regulatory networks suggested the JUN signaling pathway as a potential therapeutic target for treatment of ovarian cancer, which was validated using the JUN/AP‐1 inhibitor T‐5224. This evidence concerns the gene JUN and ovarian carcinoma.